Education
About Us
Working with TipRanks
Follow Us
Danaher Corp. (DHR)
NYSE:DHR
DHR Stock Chart & Stats
$189.35
-$1.72(-0.72%)
At close: 4:00 PM EST
$189.35
-$1.72(-0.72%)
Day’s Range― - ―
52-Week Range$171.00 - $242.80
Previous CloseN/A
Volume816.38K
Average Volume (3M)4.07M
Market Cap
$133.90B
Enterprise Value$148.16B
Total Cash (Recent Filing)$4.62B
Total Debt (Recent Filing)$18.42B
Price to Earnings (P/E)44.8
Beta0.86
Next Earnings
Apr 21, 2026EPS Estimate
1.94Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)2.23
Shares Outstanding707,139,340
10 Day Avg. Volume4,027,973
30 Day Avg. Volume4,069,989
Financial Highlights & Ratios
PEG Ratio-9.18
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue6.03
Enterprise Value/Gross Profit9.90
Enterprise Value/Ebitda21.33
Forecast
1Y Price Target
$265.00Price Target Upside39.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)8.41
Revenue Forecast (FY)$25.62B
Bulls Say, Bears Say
Bulls Say
Acquisition SynergiesDanaher's planned acquisition of Masimo is expected to produce meaningful cost and operational synergies that can drive margin expansion and earnings accretion as the businesses are integrated.
Bioprocessing Demand RecoveryMomentum in bioprocessing, including rising equipment orders and steady consumables demand driven by reshoring and new therapies, could provide above-average organic growth for the company's life-sciences exposure.
Recurring Consumables RevenueMasimo's recurring consumables model with high renewal rates supports predictable, high-margin revenue from its installed base, which can stabilize cash flow and underpin improved profitability.
Bears Say
Conservative Guidance And Valuation RiskManagement's conservative guidance and cautious pacing of expected cost benefits increase downside risk for the stock's premium valuation if end-market growth does not materialize as anticipated.
Strategic Shift And Execution RiskThe transaction represents a move toward hospital-focused medtech that increases execution and integration risk outside the company's recent life-sciences deal experience.
Target Growth ConcernsMasimo's core pulse oximetry franchise is a low-to-moderate growth business and an uneven new-product track record raises doubts about the target's ability to deliver sustained organic growth.
Danaher News
DHR FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was $171.00 and its highest was $242.80 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is $133.90B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Apr 21, 2026 which is in 28 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Jan 28, 2026. The company reported $2.23 earnings per share for the quarter, beating the consensus estimate of $2.163 by $0.067.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. pays a Quarterly dividend of $0.32 which represents an annual dividend yield of 0.53%. See more information on Danaher Corp. dividends here
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 1.94.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 707,139,340 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of $2.23 in its last earnings report, beating expectations of $2.163. Following the earnings report the stock price went down -4.755%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$265.00 (39.95% Upside)
$265.00 (39.95% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $274.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.37%
12-Months-Change
Fundamentals
Return on Equity
6.99%
Trailing 12-Months
Asset Growth
7.64%
Trailing 12-Months
Company Description
Danaher Corp.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
DHR Company Deck
DHR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized durable strengths: robust free cash flow ($5.3B), consecutive EPS and margin resilience, strong product innovation (new product revenue ~+25% YoY), and clear momentum in bioprocessing and diagnostics (Cepheid, Beckman, Leica, Radiometer). Management acknowledged Q4 margin compression (-130 bps) and pockets of weakness in life sciences consumables, academic funding, equipment orders (still below historical levels) and China policy headwinds, and set conservative FY2026 guidance (3%–6% core growth, EPS $8.35–$8.50). On balance, the company presented improving end-market momentum, disciplined cost actions (~$250M) and strong balance sheet flexibility to pursue M&A, while remaining appropriately cautious on near-term variability and execution risks.View all DHR earnings summariesDHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
DHR Stock 12 Month Forecast
Average Price Target
$265.00
▲(39.95% Upside)
Technical Analysis
Ownership Overview
8.73% Insiders
25.72% Mutual Funds
21.70% Other Institutional Investors
24.88% Public Companies and Individual Investors